<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="touching contaminated surfaces (Pant etÂ al., 2020). The typical viral" exact="infection" post="symptoms of 2019-nCoV are dry cough, running nose, fever,"/>
 <result pre="of virus (Hasan etÂ al., 2020). The first line of" exact="treatment" post="is targeted to treat the symptoms of the disease."/>
 <result pre="the mode of action of the drugs used in the" exact="treatment" post="of influenza can work successfully in the same line"/>
 <result pre="Favipiravir an antiviral drug, known to effectively inhibit the 2019-nCOV" exact="infection" post="in Vero E6 cells. An open-label non-randomized control study"/>
 <result pre="to assess the effectiveness of Favipiravir in 2019-nCOV treatment. The" exact="treatment" post="showed significant assistance in terms of health progress by"/>
 <result pre="with further research, this can be considered as a standard" exact="treatment" post="to combat the SARS-CoV-2 infection (Cai etÂ al., 2020)."/>
 <result pre="be considered as a standard treatment to combat the SARS-CoV-2" exact="infection" post="(Cai etÂ al., 2020). Further, a randomized controlled trial"/>
 <result pre="etÂ al., 2020). Further, a randomized controlled trial of combined" exact="treatment" post="of Favipiravir and Baloxavir Marboxil also carried out in"/>
 <result pre="a potent inhibitor of MERS-CoV, was inhibitive against the 2019-nCoV" exact="infection" post="since it prevents membrane fusion. Nitazoxanide, an anti-protozoal agent"/>
 <result pre="and Chloroquine were also found to be potently blocking virus" exact="infection" post="at low-micromolar concentration. Other antiviral drugs viz., Oseltamivir, and"/>
 <result pre="the various antiviral drugs are ongoing to find an effective" exact="treatment" post="for 2019-nCoV. However, since the time-period estimated for the"/>
 <result pre="and immunizations that are being researched to discover the potential" exact="treatment" post="for 2019-nCoV. As of now, countless FDA approved antiviral"/>
 <result pre="countless FDA approved antiviral agents are in use for the" exact="treatment" post="of 2019-nCoV viral infection. However, numerous examples exist in"/>
 <result pre="of the chosen protease inhibitors are utilized principally for the" exact="treatment" post="of Herpesvirus, Human Immunodeficiency Virus (HIV), Respiratory Syncytial Infection"/>
 <result pre="flu A viruses, and can also be used for the" exact="treatment" post="of 2019-nCoV. In this scenario, sequence and structure analysis"/>
 <result pre="one of the most crucial mechanisms of action especially in" exact="treatment" post="against MERS-CoV and EBOV (Siegel etÂ al., 2017; Jordan"/>
 <result pre="HuangD., ZhangJ., ZhangS., WangF., LiuJ., ChenL., â€¦ LiuL. (2020). Experimental" exact="treatment" post="with favipiravir for COVID-19: An open-label control study. Engineering."/>
 <result pre="Journal of Chemical Physics, 121(1), 108â€&quot;116. 10.1063/1.174075315260527 LuH. (2020). Drug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV). Bioscience Trends, 14(1),"/>
 <result pre="phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the" exact="treatment" post="of Ebola and emerging viruses. Journal of Medicinal Chemistry,"/>
 <result pre="T. (2005). Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virology Journal, 2(1), 6910.1186/1743-422X-2-6916115318 WangM., CaoR., ZhangL.,"/>
</results>
